Insulin biosimilars may be a predictive signal for how the market will respond to the increased development of interchangeable biosimilars.
Manufacturers of reference biologics will protect their market share by introducing authorized biosimilars, new formulations and delivery mechanisms, and by increasing list prices so that deeper rebates can also be offered.
Manufacturer Mallinckrodt reaches $260 million settlement resolving allegations of rebate underpayment and kickbacks
The manufacturer allegedly improperly calculated and underpaid rebates to state Medicaid programs for its drug H.P. Acthar Gel and provided illegal copay subsidies that encouraged patients to purchase its drugs.
Non-profit group estimates the theoretical cost of Build Back Better Act price inflation penalties on manufacturers for Part D
Council for Informed Drug Spending Analysis (CIDSA) estimated that $150 million in Medicare Part D-related penalties would have been assessed in Q1 2022 based on the previous year’s inflation rate and manufacturer price increases.
The estimate does not include penalties related to commercial sales which would also be applied.
The inflation penalties would take effect starting in Q1 2023.